The clinical and economic burden of systemic sclerosis related interstitial lung disease

Kathleen Morrisroe, Wendy Stevens, Joanne Sahhar, Gene-Siew Ngian, Nava Ferdowsi, Dylan Hansen, Shreeya Patel, Catherine L. Hill, Janet Roddy, Jennifer Walker, Susanna Proudman, Mandana Nikpour

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Objective: To quantify the burden of interstitial lung disease (ILD) in SSc. Methods: Clinical data for SSc patients enrolled in the Australian Scleroderma Cohort Study were linked with healthcare databases for the period 2008-2015. ILD was defined by characteristic fibrotic changes on high-resolution CT (HRCT) lung, while severity was defined by the extent lung involvement on HRCT (mild <10%, moderate 10-30%, severe >30%). Determinants of healthcare cost were estimated using logistic regression. Results: SSc-ILD patients utilized more healthcare resources, including hospitalization, emergency department presentation and ambulatory care services, than those without ILD with a total cost per patient of AUD$48 368 (26 230-93 615) vs AUD$33 657 (15 144-66 905), P<0.001) between 2008-2015. Healthcare utilization was associated with an annual median (25th-75th) excess cost per SSc-ILD patient compared with those without ILD of AUD$1192 (807-1212), P<0.001. Increasing ILD severity was associated with significantly more healthcare utilization and costs with an annual excess cost per patient with severe ILD compared with mild ILD of AUD$2321 (645-1846), P<0.001. ILD severity and the presence of coexistent PAH were the main determinants of overall healthcare cost above median for this SSc-ILD cohort (OR 5.1, P<0.001, and OR 2.6, P=0.01, respectively). Furthermore, SSc-ILD patients reported worse physical HRQoL compared with those without ILD [34.3 (10.5) vs 39.1 (10.8), P<0.001], with a progressive decline with increasing ILD severity (P=0.002). Conclusion: SSc-ILD places a large burden on the healthcare system and the patient through poor HRQoL in addition to incremental healthcare resource utilization and associated direct cost.

Original languageEnglish
Pages (from-to)1878-1888
Number of pages11
JournalRheumatology (United Kingdom)
Volume59
Issue number8
DOIs
Publication statusPublished - 1 Aug 2020
Externally publishedYes

Keywords

  • economic burden
  • health-related quality of life
  • healthcare utilization
  • interstitial lung disease
  • scleroderma
  • Systemic sclerosis

Fingerprint

Dive into the research topics of 'The clinical and economic burden of systemic sclerosis related interstitial lung disease'. Together they form a unique fingerprint.

Cite this